Genfit SA logo
Genfit SA GNFT

Annual report 2024
added 02-21-2026

report update icon

Genfit SA Interest Expense 2011-2026 | GNFT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.
Includes:
  • Interest on bank loans
  • Interest on corporate bonds
  • Interest on leases
  • Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Genfit SA

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
4.68 M 4.55 M 4.34 M 4.85 M 11.6 M 11.3 M 11 M 2.31 M - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
11.6 M 2.31 M 6.83 M

Interest Expense of other stocks in the Biotechnology industry

Issuer Interest Expense Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
4.66 M - 2.43 % $ 254 M germanyGermany
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
3.71 M $ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
268 K - -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
722 K - - $ 866 M chinaChina
Acer Therapeutics Acer Therapeutics
ACER
432 K - 2.71 % $ 14 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-5.01 K - -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-133 K $ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-2.71 M $ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
103 K - 3.77 % $ 22.4 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
1.6 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-15.9 M $ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
43.1 M $ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-93 K - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-6 K - -4.8 % $ 255 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
8.23 M - - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
18.9 M - - $ 3.45 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
4.34 M - - $ 789 M usaUSA
Certara Certara
CERT
6.34 M $ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
9 K - 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
344 K - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-257 K - -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
476 K - - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
444 K - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
31.5 M - -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
399 K $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
25.7 M $ 24.0 0.5 % $ 2.93 B usaUSA
Codexis Codexis
CDXS
-10.4 M $ 0.99 -3.28 % $ 72.7 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
13.1 M - - $ 1.2 B usaUSA
CohBar CohBar
CWBR
223 K - -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
52 K - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
52 K - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
16.4 M - - $ 2.18 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
4.9 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
29.5 M - - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
1.06 M $ 17.54 -3.36 % $ 450 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
2.27 M - 7.55 % $ 38.1 M usaUSA